Under The Tree BioPharmaceuticals, or UTT BioPharma, is a pharmaceutical company specialising in the research and production of botanical drugs with a particular interest in the cannabis genus. Our immediate goal is to streamline the development and manufacturing of cannabinoid based medicine.
UTT BioPharma consists of a group of experts with the skills to run the process of cultivating, fractionating and purifying large quantities of raw materials in accordance with GxP standards and producing medical grade products following pharmaceutical industry guidelines.
We believe that the cannabis plant holds the key to significantly improving the lives of patients around the world. Our mission is to develop and build the infrastructure required to conduct the research enabling access to these benefits.
To achieve this UTT BioPharma has built a continuously growing network of experts and research institutes, promoting the integration of current global knowledge into all aspects of the development process.
While the provision of safe and effective cannabis derived medications is our priority, we want to help shape the changing political landscape, by providing high quality and evidenced based information to the public, law makers and patients. This will accelerate the development of a medical, political and social landscape in favour of a controlled entry of cannabis derived therapeutics into the market.
A biopharmaceutical engineer by profession, Sergio has a invaluable experience in the pharmaceutical manufacturing sector from his time at CSL Behring and Kedrion S.p.A.
Sergio co-founded UTT BioPharma to develop and commercialize novel synergic medications for unmet medical needs. Sergio has laid down the framework for the complete GMP ‘seed to pill’ process based on his prior experience in the biologics sector, and has built a GMP supply chain with a network of manufacturers.
A qualified pharmacologist, Abdul was encapsulated by the therapeutic opportunities present in the cannabis plant.
Abdul co-founded UTT BioPharma with the aim of developing synergic therapeutics from the plant. In order to achieve this goal, Abdul has put together a team of reputable scientists at the University of Melbourne to undertake this research.
As a biomolecular and chemical engineer, Feroz Mujtaba Rahman has vast experience in R&D, qualification and validation areas that he gained while working at CSL Behring.
Feroz specialises in processes driven from small scale R&D to commercial manufacturing in strict regulatory guidelines.
Prof Terence O’Brien, The University of Melbourne, Melbourne, Australia
Dr Tina Soulis, The Florey Institute, Melbourne, Australia
Prof Nigel Bunnett, Monash University, Melbourne, Australia
Dr Miriam Melis, University of Cagliari, Cagliari, Italy
Prof Steven Petrou, The Florey Institute and The University of Melbourne, Melbourne, Australia
Prof David Castle, St Vincents Hospital and The University of Melbourne, Melbourne, Australia
Prof Geoff Stevens, The University of Melbourne, Melbourne, Australia
Dr Liana Fattore, National Research Council, Rome, Italy
Prof Toni Bacic, The University of Melbourne, Melbourne, Australia
Prof Ian Woodrow, The University of Melbourne, Melbourne, Australia